Isatuksimabi yhdistelmänä uusien aineiden kanssa RRMM:ssä - Master Protocol
Vaiheen 1-2 sateenvarjokoe Isatuksimabin arvioimiseksi deksametasonin kanssa tai ilman sitä yhdessä uusien aineiden kanssa verrattuna Isatuksimabiin pomalidomidin ja deksametasonin kanssa uusiutuneessa tai refraktaarisessa multippeli myeloomassa (RRMM) - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Trial Transparency email recommended (Toll free number for US & Canada)
- Puhelinnumero: option 6 800-633-1610
- Sähköposti: contact-us@sanofi.com
Opiskelupaikat
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Rekrytointi
- Investigational Site Number : 0360006
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Valmis
- Investigational Site Number : 0360003
-
Melbourne, Victoria, Australia, 3065
- Rekrytointi
- Investigational Site Number : 0360002
-
Richmond, Victoria, Australia, 3121
- Rekrytointi
- Investigational Site Number : 0360001
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Etelä -Korea, 03722
- Rekrytointi
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Etelä -Korea, 06351
- Rekrytointi
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Etelä -Korea, 03080
- Rekrytointi
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Etelä -Korea, 06591
- Rekrytointi
- Investigational Site Number : 4100003
-
-
-
-
-
Jerusalem, Israel, 9112001
- Rekrytointi
- Investigational Site Number : 3760002
-
Ramat Gan, Israel, 5262100
- Rekrytointi
- Investigational Site Number : 3760003
-
Tel Aviv, Israel, 6423906
- Rekrytointi
- Investigational Site Number : 3760001
-
-
-
-
Reggio Emilia
-
Meldola, Reggio Emilia, Italia, 47014
- Rekrytointi
- Investigational Site Number : 3800001
-
-
-
-
-
Athens, Kreikka, 115 28
- Rekrytointi
- Investigational Site Number : 3000001
-
Athens, Kreikka, 106 76
- Rekrytointi
- Investigational Site Number : 3000002
-
-
-
-
-
Oslo, Norja, 0450
- Rekrytointi
- Investigational Site Number : 5780001
-
-
-
-
Puerto Rico
-
Hato Rey, Puerto Rico, Puerto Rico, 00917
- Valmis
- Puerto Rico Medical Research Center- Site Number : 8400005
-
-
-
-
-
Lille, Ranska, 59037
- Rekrytointi
- Investigational Site Number : 2500002
-
Nantes, Ranska, 44093
- Rekrytointi
- Investigational Site Number : 2500001
-
Paris, Ranska, 75013
- Rekrytointi
- Investigational Site Number : 2500003
-
Paris, Ranska, 75015
- Rekrytointi
- Investigational Site Number : 2500004
-
-
-
-
-
Frankfurt, Saksa, 60590
- Rekrytointi
- Investigational Site Number : 2760006
-
Lübeck, Saksa, 23562
- Rekrytointi
- Investigational Site Number : 2760008
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35233
- Valmis
- University of Alabama at Birmingham- Site Number : 8400001
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Winship Cancer Institute of Emory University- Site Number : 8400010
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60612
- Valmis
- University of Illinois-Chicago - College of Medicine- Site Number : 8400007
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109
- Rekrytointi
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263
- Rekrytointi
- Roswell Park Cancer Institute- Site Number : 8400008
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43210
- Rekrytointi
- The Ohio State University- Site Number : 8400012
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Participant must be 18 years of age inclusive or older.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
-
Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).
-
RRMM with measurable disease:
- Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
- Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
- Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
-
Men or woman or childbearing potential should agree to use contraception.
-
Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.
-
Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.
-
Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.
-
Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.
Exclusion Criteria:
- Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
- Uncontrolled infection within 14 days prior to first study intervention administration.
- Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
- Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
- Uncontrolled or active hepatitis B virus (HBV) infection.
- Active hepatitis C virus (HCV) infection.
- Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
- Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
- Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
- Participants with a contraindication to treatment.
- Vaccination with a live vaccine 4 weeks before the start of the study.
- Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
- Hemoglobin <8 g/dL.
- Platelets <50 × 10^9/L.
- Absolute neutrophil count <1.0 × 10^9/L.
- Creatinine clearance <30 mL/min/1.73m2.
- Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
- Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
- Patients with grade 3 or 4 hypercalcemia.
Substudy 01:
-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.
Substudy 02:
- History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
- Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
- Prothrombin time or INR >1.5 × upper limit of normal (ULN).
Substudy 03:
- Current corneal epithelial disease except mild punctate keratopathy.
- Patients who have received prior therapy with belantamab mafodotin.
Substudy 04:
- Central nervous system or leptomeningeal disease.
- Medical history of seizure.
- Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
- Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
- Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).
Substudy 05:
- Participant unable to swallow tablets.
Substudy 06:
- History of active autoimmune disorders.
- History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
- Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
- Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
- Patient with chronic active EBV infection.
- Patients with known history of HLH.
- Hemoglobin < 9 g/dL.
- Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Active Comparator: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Capsule; Route of administration: Oral
Muut nimet:
|
|
Kokeellinen: isatuximab + SAR439459 + dexamethasone (Substudy 02)
SAR439459 in combination with isatuximab and dexamethasone Part 1: 2 dose levels (DLs) of IV SAR439459:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for injection; Route of administration: Intravenous |
|
Kokeellinen: isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)
Belantamab mafodotin in combination with isatuximab and dexamethasone Part 1: 1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:
Part 2:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Muut nimet:
|
|
Kokeellinen: Isatuximab + pegenzileukin (Substudy 04)
Pegenzileukin in combination with isatuximab Part 1- dose escalation:
Part 1 - dose optimization:
Part 2 (dose expansion):
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Muut nimet:
|
|
Kokeellinen: Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)
Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.
Part 1- dose optimization:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: tablet; route of administration: oral
Muut nimet:
|
|
Kokeellinen: Isatuximab + evorpacept + dexamethasone (Substudy 06)
Isatuximab in combination with evorpacept and dexamethasone Part 1- dose escalation:
Part 2- dose expansion:
|
Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
Muut nimet:
Pharmaceutical form: Tablet; Route of administration: Oral Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
Aikaikkuna: Through the end of cycle 1 (approximately 6 weeks)
|
Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers. |
Through the end of cycle 1 (approximately 6 weeks)
|
|
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Uusien aineiden (kokeellisten aseiden) ja isatusimabin (CtRough) pitoisuus (CTROUGH)
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Ensimmäisen infuusion (CMAX) jälkeen havaittu enimmäiskonsentraatio belumosudilille - Avusta 05
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Aika saavuttaa Cmax (TMAX) belumosudilille - AlaDy 05
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Alue pitoisuuden alla verrattuna aikakäyrään, joka on laskettu käyttämällä trapetsoidista menetelmää välillä 0 - 8H (AUC0-8H) belumosudilille - AlaDy 05
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Ensimmäisen infuusion (CMAX) jälkeen havaittu enimmäiskonsentraatio evoorpacept - subdyy 06
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Aika saavuttaa Cmax (TMAX) evoorpacept - Abdyy 06
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Pinta-alaisena pitoisuuden alla verrattuna aikakäyrään, joka on laskettu trapetsoidisella menetelmällä annostusvälin kautta evoorpaceptille (AUC0-T)- Abdyy 06
Aikaikkuna: Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
Useita aikapisteitä syklin 1 aikana. Sykli on 28 päivää.
|
|
|
Part 1 (dose finding, experimental substudies): ORR
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, controlled experimental substudies): ORR
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 1 (dose finding, experimental substudies): VGPR or better
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Part 2 (expansion, independent experimental substudies): VGPR or better
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Clinical benefit rate (CBR) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Duration of Response (DOR) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to First Response (TT1R) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Time to Best Response (TTBR) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Progression-free survival (PFS) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Overall Survival (OS) in each treatment arm
Aikaikkuna: Up to approximately 28 months after the First patient in or scheduled assessment
|
OS is defined as the time from the date of first treatment to death from any cause. |
Up to approximately 28 months after the First patient in or scheduled assessment
|
|
Immunogenicity of isatuximab and novel agents
Aikaikkuna: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab. |
Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
|
|
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies). |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
|
|
SRE Incidence for control and experimental arms- Substudy 02
Aikaikkuna: Continuous throughout study assessment (up to approximately 28 months)
|
SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
Aikaikkuna: Continuous throughout study assessment (up to approximately 28 months)
|
Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE. |
Continuous throughout study assessment (up to approximately 28 months)
|
|
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
Aikaikkuna: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events. |
On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
|
|
To assess patient-reported visual functioning for experimental arm only -Substudy 03
Aikaikkuna: On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
An NEI VFQ-25 will be used to assess patient-reported visual functioning. |
On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojohtaja: Clinical Sciences & Operations, Sanofi
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- ACT16482
- 2020-003024-16 (EudraCT-numero)
- U1111-1244-2598 (Rekisterin tunniste: ICTRP)
- 2024-514988-25 (Rekisterin tunniste: CTIS)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .